Arrowhead Pharmaceuticals (NASDAQ:ARWR) Earns Buy Rating from Chardan Capital

Key Points

• Chardan Capital has restated a "buy" rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR) with a price objective of $60.00, indicating a potential upside of 265.41% from its current price.
• Despite the optimistic outlook from Chardan, analysts from Royal Bank of Canada and Citigroup have lowered their price targets, with consensus ratings suggesting a "Moderate Buy" position overall.
• Arrowhead Pharmaceuticals reported a quarterly loss of ($1.26) EPS, missing analysts' expectations, and their revenue for the quarter was $27.77 million, below the expected $29.01 million.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report)'s stock had its "buy" rating reiterated by equities researchers at Chardan Capital in a research report issued on Monday,Benzinga reports. They presently have a $60.00 price objective on the biotechnology company's stock. Chardan Capital's price target points to a potential upside of 219.49% from the company's previous close. Chardan Capital also issued estimates for Arrowhead Pharmaceuticals' FY2025 earnings at ($0.16) EPS and FY2026 earnings at ($3.97) EPS.

ARWR has been the subject of a number of other research reports. Royal Bank Of Canada cut their price objective on shares of Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating for the company in a research note on Friday, August 8th. Wall Street Zen lowered shares of Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, July 18th. HC Wainwright reiterated a "buy" rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday, May 20th. Citigroup lowered their target price on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating for the company in a research note on Tuesday, May 13th. Finally, TD Cowen upgraded Arrowhead Pharmaceuticals to a "strong-buy" rating in a report on Monday, July 28th. Three investment analysts have rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $43.14.

Arrowhead Pharmaceuticals Price Performance

ARWR traded down $1.21 during trading on Monday, reaching $18.78. The stock had a trading volume of 5,000,537 shares, compared to its average volume of 1,923,443. The business has a 50-day moving average of $16.59 and a 200-day moving average of $15.95. Arrowhead Pharmaceuticals has a one year low of $9.57 and a one year high of $27.34. The company has a debt-to-equity ratio of 0.39, a quick ratio of 4.87 and a current ratio of 4.87. The stock has a market cap of $2.60 billion, a PE ratio of -14.67 and a beta of 0.94.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The firm had revenue of $27.77 million during the quarter, compared to analysts' expectations of $29.01 million. During the same quarter in the previous year, the business earned ($1.38) EPS. As a group, equities research analysts anticipate that Arrowhead Pharmaceuticals will post -2.42 EPS for the current fiscal year.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ARWR. Wells Fargo & Company MN grew its position in shares of Arrowhead Pharmaceuticals by 43.1% in the 4th quarter. Wells Fargo & Company MN now owns 62,886 shares of the biotechnology company's stock worth $1,182,000 after buying an additional 18,933 shares during the period. Bank of Montreal Can increased its stake in shares of Arrowhead Pharmaceuticals by 13.3% during the fourth quarter. Bank of Montreal Can now owns 15,018 shares of the biotechnology company's stock valued at $282,000 after purchasing an additional 1,759 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at approximately $651,000. Summit Investment Advisors Inc. boosted its position in shares of Arrowhead Pharmaceuticals by 2.2% in the 4th quarter. Summit Investment Advisors Inc. now owns 37,994 shares of the biotechnology company's stock worth $714,000 after purchasing an additional 803 shares in the last quarter. Finally, Barclays PLC grew its stake in shares of Arrowhead Pharmaceuticals by 13.0% in the 4th quarter. Barclays PLC now owns 312,560 shares of the biotechnology company's stock worth $5,876,000 after buying an additional 35,950 shares during the last quarter. 62.61% of the stock is owned by hedge funds and other institutional investors.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.